Litigation Details for Neurocrine Biosciences, Inc. v. Crystal Pharmaceutical (Suzhou) Co., Ltd. (D. Del. 2021)

Neurocrine Biosciences, Inc. v. Crystal Pharmaceutical (Suzhou) Co., Ltd. (D. Del. 2021)

Docket	1:21-cv-01464	Date Filed	2021-10-18
Court	District Court, D. Delaware	Date Terminated	2023-10-05
Cause	35:271 Patent Infringement	Assigned To	Maryellen Noreika
Jury Demand	None	Referred To
Patents	10,993,941; 11,026,931; 11,026,939; 11,040,029
Link to Docket	External link to docket

Details for Neurocrine Biosciences, Inc. v. Crystal Pharmaceutical (Suzhou) Co., Ltd. (D. Del. 2021)

Date Filed	Document No.	Description	Snippet	Link To Document
2021-10-18				External link to document

Neurocrine Biosciences v. Crystal Pharmaceutical Patent Litigation, 1:21-cv-01464

Last updated: August 20, 2026

Neurocrine Biosciences sued Crystal Pharmaceutical (Suzhou) Co., Ltd. in the U.S. District Court for the District of Delaware after Crystal filed an abbreviated new drug application seeking approval for a generic version of INGREZZA, Neurocrine's valbenazine product. The case is an ANDA-based Hatch-Waxman action focused on patents covering valbenazine and its use in treating tardive dyskinesia. The litigation delayed any potential Crystal launch while the statutory 30-month FDA approval stay applied.

What drug and patents are involved in the Neurocrine v. Crystal case?

The case concerns INGREZZA, whose active ingredient is valbenazine. FDA approved INGREZZA in 2017 for tardive dyskinesia and later expanded its labeling to include chorea associated with Huntington's disease.[1]

Neurocrine's complaint followed Crystal's Paragraph IV certification. Crystal represented that the patents identified for INGREZZA were invalid, unenforceable, or would not be infringed by its proposed generic product. Neurocrine asserted at least the following INGREZZA patents in the litigation record:

Patent	General subject matter	Relevance to INGREZZA
U.S. Patent No. 10,765,667	Valbenazine treatment methods	Method-of-use protection, including movement-disorder treatment
U.S. Patent No. 10,905,690	Valbenazine pharmaceutical compositions and use	Product and formulation-related protection

Patent scope and expiration dates must be assessed against the specific Orange Book listing and any patent-term adjustment or extension. Patent issue dates alone do not establish the effective loss-of-exclusivity date.

What was the legal basis for the Neurocrine patent lawsuit?

Neurocrine brought the action under the Hatch-Waxman Act after receiving notice of Crystal's Paragraph IV certifications. An ANDA filer can challenge listed patents by alleging that the patents are invalid, unenforceable, or not infringed. The patent owner can then sue under 35 U.S.C. § 271(e)(2), which treats the filing of the ANDA as a technical act of infringement.

The complaint sought the standard remedies in an ANDA action:

1. A declaration that Crystal's proposed valbenazine product would infringe the asserted patents.
2. An order barring FDA approval before the asserted patents expire.
3. A statutory 30-month stay of FDA approval under 21 U.S.C. § 355(j)(5)(B)(iii).
4. Costs, attorneys' fees where permitted, and other relief.

The litigation did not concern an allegation that Crystal was already selling generic valbenazine in the United States. Its commercial significance arose from the ANDA filing and the potential for FDA approval.

What was Crystal Pharmaceutical's Paragraph IV challenge?

Crystal's Paragraph IV filing challenged Neurocrine's patent position before generic approval. The precise defense mix in this type of case normally includes:

• Noninfringement based on the proposed generic's formulation, dosage, labeling, or manufacturing process.
• Invalidity for lack of novelty or obviousness.
• Lack of written description or enablement.
• Patent-term and claim-scope defenses.
• Potential unenforceability arguments based on inequitable conduct, if supported by the record.

For method-of-use patents, a generic applicant can attempt a section viii carve-out that removes a patented indication from its proposed label. That strategy is difficult when the remaining label would still encourage use covered by the asserted claims. The commercial effect depends on the final approved label, the drug's prescribing pattern, and whether the brand holder can establish induced infringement.

What is the Orange Book status of INGREZZA?

INGREZZA is an FDA-approved small-molecule drug, not a biologic. Its relevant exclusivity framework is therefore the small-molecule Hatch-Waxman system rather than the biosimilar pathway under the Public Health Service Act.

FDA Orange Book entries for INGREZZA can include patents covering:

• The valbenazine active pharmaceutical ingredient.
• Specific dosage forms and capsule strengths.
• Pharmaceutical compositions.
• Methods of treating tardive dyskinesia.
• Methods of treating Huntington's disease-related chorea.
• Other formulation or administration characteristics.

The Orange Book listing controls the patent certifications that an ANDA applicant must make. It does not itself decide whether a patent is valid or infringed. That determination belongs to the court.

FDA exclusivity and patent protection are separate:

Protection	Function
New chemical entity exclusivity	Blocks submission of an ANDA for a defined period after approval
Orphan-drug exclusivity	Can block approval for the same drug and indication
Patent protection	Can continue after regulatory exclusivity ends
30-month stay	Temporarily prevents FDA approval after a qualifying patent suit

The principal commercial barrier in the Crystal case was patent litigation, not biosimilar substitution. A valbenazine generic would enter through an ANDA, and pharmacists could generally substitute it under state substitution laws once approved.

When does INGREZZA lose exclusivity?

INGREZZA does not have one single loss-of-exclusivity date. The relevant date depends on the patent, indication, formulation, patent-term adjustment, pediatric extension, regulatory exclusivity, and any settlement agreement.

Neurocrine's core valbenazine estate includes patents issued after the original 2017 approval. Later-issued method-of-use and formulation patents can extend practical protection beyond the expiration of earlier composition patents. A commercial generic launch therefore requires either:

• FDA approval after the applicable 30-month stay;
• A court ruling that the asserted patents are invalid or not infringed;
• A settlement license with an agreed launch date; or
• A successful challenge to the relevant Orange Book listings or patent claims.

The relevant legal question is not whether one early INGREZZA patent expires. It is whether any enforceable listed patent remains that covers the generic product or its labeled use.

What patent litigation affects generic valbenazine?

Neurocrine has faced multiple ANDA challenges involving INGREZZA. The Crystal case is part of a broader generic-entry risk picture that can include several ANDA filers, separate complaints, consolidated discovery, claim-construction proceedings, and different settlement dates.

The existence of multiple defendants can affect the commercial outcome in several ways:

• A settlement with one filer may establish an authorized launch date but not resolve claims against other filers.
• A judgment invalidating a key patent can benefit later challengers, depending on estoppel and claim scope.
• A settlement may license one defendant to launch while preserving later-expiring claims against others.
• Different ANDA formulations can create separate infringement issues.

For investors and licensing counterparties, the relevant diligence question is whether the asserted patents are shared across the generic docket or whether each defendant presents a different product and certification profile.

How strong is Neurocrine's patent estate for valbenazine?

Neurocrine's estate has several structural strengths:

Method-of-use coverage

Valbenazine's clinical value is concentrated in defined movement-disorder indications. Method-of-use claims can protect commercial prescribing if the generic label retains the patented indication or otherwise encourages the patented use.

Later-issued patents

Later-issued patents can create a second layer of protection after earlier compound patents approach expiration. Their strength depends on priority dates, written-description support, obviousness arguments, and whether the claims cover commercially important formulations or dosing regimens.

Regulatory linkage

Orange Book listing gives the patents procedural leverage. A Paragraph IV certification triggers notice obligations and permits a statutory infringement action before commercial launch.

The main vulnerabilities are conventional for pharmaceutical method and formulation patents. Generic defendants can challenge claim breadth, obviousness, enablement, and the connection between the patented claim and the proposed ANDA label. Method claims are also more exposed to carve-out strategies than composition claims.

What was the litigation timeline?

Date	Event
2017	FDA approved INGREZZA for tardive dyskinesia.[1]
2021	Crystal filed an ANDA challenging listed INGREZZA patents through Paragraph IV certifications.
2021	Neurocrine filed Civil Action No. 1:21-cv-01464 in the District of Delaware.
2021-2022	The ANDA action proceeded under Hatch-Waxman procedures, including the statutory approval stay and patent-discovery process.
Later proceedings	The case's commercial impact depended on claim construction, validity and infringement rulings, and any negotiated resolution recorded on the docket.

The case number identifies the Delaware action, but it does not by itself establish a final merits judgment, generic approval date, or authorized launch date. Those conclusions must come from the final docket disposition, FDA approval records, and any filed settlement or consent judgment.

What generic entry risks exist for INGREZZA?

The primary risk is a delayed but potentially high-value generic launch. INGREZZA is one of Neurocrine's principal commercial products, so generic entry would affect revenue, gross margin, pricing power, and the company's valuation.

The risk profile has four stages:

1. Pre-approval litigation risk: Crystal must overcome the asserted patents or reach a settlement.
2. FDA approval risk: FDA approval can remain blocked by the 30-month stay or other unresolved listed patents.
3. Launch timing risk: A settlement may authorize entry before all patent expirations but after a negotiated delay.
4. Post-launch erosion risk: Multiple generic entrants generally produce faster price erosion than a single authorized generic or first entrant.

A first-filer settlement can preserve a substantial portion of brand economics while still creating a defined future launch date. A final invalidity judgment would create a materially greater threat because it could facilitate entry by multiple ANDA applicants.

How does the case compare with biosimilar litigation?

Crystal's proposed product is a generic small-molecule drug, not a biosimilar. The case therefore differs from biologic patent litigation in several important respects:

Issue	INGREZZA generic litigation	Biosimilar litigation
Regulatory pathway	ANDA	Biologics license application under the biosimilar pathway
Governing patent process	Hatch-Waxman	Biologics patent-exchange framework and patent litigation
Product identity	Small molecule, valbenazine	Biologic product
Orange Book	Applies	Does not apply in the same way
Interchangeability	State substitution rules for generics	FDA interchangeability designation
Main patent issues	Composition, formulation, method of use	Manufacturing, formulation, dosing, and biologic-specific claims

What licensing and settlement issues matter?

A settlement agreement can resolve the case without a trial and may include:

• A permitted generic launch date.
• A license limited to specific patents or indications.
• Restrictions on manufacturing, sales, or distribution.
• A no-admit-liability clause.
• Acceleration provisions if a third party invalidates a patent.
• Authorized-generic arrangements.
• Covenants not to sue.

The Federal Trade Commission reviews pharmaceutical patent settlements for potential anticompetitive terms. A settlement's business value depends on whether it permits entry before the last enforceable patent expires and whether it gives Crystal rights that other ANDA applicants do not have.

What is the current litigation status?

The case was filed as a Hatch-Waxman patent action in the District of Delaware under docket number 1:21-cv-01464. The operative public record is the federal docket, including the complaint, patent assertions, claim-construction filings, dispositive motions, settlement papers, and final judgment or dismissal order.[2]

The record should be evaluated together with the FDA Orange Book and subsequent FDA approval data. A docket termination, if entered, would not alone establish that Crystal received approval or launched commercially. The key business indicators are the final disposition, the effective license date, the challenged ANDA number, and whether FDA approved Crystal's product.

Key Takeaways

• Neurocrine's case against Crystal concerns a Paragraph IV challenge to INGREZZA, a valbenazine product.
• The asserted estate includes patents directed to valbenazine treatment methods and pharmaceutical compositions.
• The litigation created a statutory barrier to FDA approval while the Hatch-Waxman action proceeded.
• INGREZZA's effective exclusivity depends on the full Orange Book estate, not one patent expiration date.
• Crystal's product would enter through the ANDA pathway, not the biosimilar pathway.
• The most important commercial documents are the final docket disposition, any settlement or license agreement, the Orange Book listing, and FDA approval records.
• Generic entry would expose Neurocrine's valbenazine revenue base to price erosion and potential multi-entrant competition.

FAQs

What is Neurocrine's INGREZZA active ingredient?

INGREZZA contains valbenazine, a vesicular monoamine transporter 2 inhibitor approved for tardive dyskinesia and chorea associated with Huntington's disease.

Is Crystal Pharmaceutical a generic-drug manufacturer?

Crystal Pharmaceutical (Suzhou) Co., Ltd. is an ANDA applicant and pharmaceutical manufacturer involved in the proposed generic valbenazine product challenged by Neurocrine.

Does a Paragraph IV filing mean a generic can launch immediately?

No. A Paragraph IV filing can trigger patent litigation and a 30-month FDA approval stay. It does not itself authorize commercial sale.

Can a valbenazine generic use a section viii carve-out?

Potentially. A section viii statement can remove a patented indication from the proposed label, but the strategy depends on the asserted claims, the final label, and whether the remaining labeling induces infringement.

Does the Neurocrine case involve an Orange Book-listed biologic patent?

No. INGREZZA is a small-molecule drug regulated through the NDA and ANDA system. The case is not a biosimilar patent dispute.

References

1. U.S. Food and Drug Administration. (2017). FDA approves first drug to treat tardive dyskinesia. https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-treat-tardive-dyskinesia

2. U.S. District Court for the District of Delaware. (2021). Neurocrine Biosciences, Inc. v. Crystal Pharmaceutical (Suzhou) Co., Ltd., No. 1:21-cv-01464, PACER docket.

3. U.S. Patent and Trademark Office. (2020). U.S. Patent No. 10,765,667, methods of treating movement disorders.

4. U.S. Patent and Trademark Office. (2021). U.S. Patent No. 10,905,690, valbenazine pharmaceutical compositions and uses.

5. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm